Please assess the completion status of the following clinical trial:

Trial Title: STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years of age~* All patients with newly diagnosed NHL and HL~* Scheduled to receive anthracycline-based therapy~Exclusion Criteria:~* Statin use or Statin use is indicated based on guidelines~* Pregnancy or breastfeeding~* Unable to provide informed consent~* Unexplained persistent elevation of transaminases (\>3 times upper limits of normal)~* Concomitant use of cyclosporine~* Renal failure: estimated glomerular filtration \<45 mL/min/1.73 m2~* Contraindication to a CMR (metallic object, severe claustrophobia, pacemaker, vascular clip~* LVEF of \<50% at baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)
- Atorvastatin (Type: EXPERIMENTAL): Atorvastatin will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)

Based on this trial design, predict the completion outcome and termination type (if applicable).